Drug Profile
Luminespib - Vernalis
Alternative Names: AUY-922; NVP-AUY-922; VER-52296Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Cancer Research Technology; The Institute of Cancer Research; Vernalis
- Developer Memorial Sloan-Kettering Cancer Center; Novartis; Sarah Cannon Research Institute; SCRI Development Innovations; University of Texas M. D. Anderson Cancer Center; University of Toronto; Vernalis
- Class Amides; Antineoplastics; Isoxazoles; Morpholines; Resorcinols; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Discontinued Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; HER2 positive breast cancer; Lymphoma; Multiple myeloma; Myeloproliferative disorders; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 13 Apr 2020 Luminespib - Vernalis is available for licensing as of 13 Apr 2020. https://www.vernalis.com/
- 13 Apr 2020 Discontinued - Phase-I for Colorectal cancer (Combination therapy, Second-line therapy or greater) in USA (IV)
- 13 Apr 2020 Discontinued - Phase-I for Gastric cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Germany, South Korea, Switzerland, Taiwan (IV)